On November 27, 2018 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that Dr. David Ralph, Director of Drug Development and IP Manager of Navidea, will be presenting at the RSNA 104th Scientific Assembly and Annual Meeting, which is taking place November 25-30, 2018 in Chicago, IL (Press release, Navidea Biopharmaceuticals, NOV 27, 2018, View Source [SID1234531659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will highlight an abstract evaluated and selected through a competitive, blind peer-review process. The presentation will focus on recent imaging results obtained from Kaposi Sarcoma patients who have received 99mTc-tilmanocept by either a subcutaneous or an intravenous route of administration.

Oral Presentation Details
Presentation Title: Planar and SPECT/CT Imaging in Human Immunodeficiency Virus (HIV) Subjects Diagnosed with Kaposi Sarcoma (KS) using Intravenous 99mTc-tilmanocept
Abstract: SSK19-06
When: Wednesday, November 28 at 11:20am CT
Where: McCormick Place, Chicago, IL
Room: S504AB

RSNA 2018 annual meeting provides a hands on experience with cutting-edge tech, including artificial intelligence, 3D printing and virtual reality. Sessions cover the latest research and provides a platform to enhance skills and network. Over 70,000 people will attend this annual meeting.

More details on the annual meeting, including the full agenda can be found at View Source